https://www.biopharmawatch.com/news/NYXH/nyxoah-breathe-study-first-patient-implanted BiopharmaWatch en 2026-09-07T20:05:00.000Z Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System https://www.biopharmawatch.com/news/ASND/ascendis-endocrinology-rare-disease-data-espe-2026 BiopharmaWatch en 2026-09-07T11:00:00.000Z Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 https://www.biopharmawatch.com/news/NVO/novo-nordisk-step-young-phase-3-results BiopharmaWatch en 2026-09-07T10:00:00.000Z Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-07 BiopharmaWatch en 2026-09-07T07:15:28.530Z Biotech Catalysts to Watch: Key Developments for September 2026 https://www.biopharmawatch.com/news/ORBS/eightco-holdings-assets-openai-beast-industries BiopharmaWatch en 2026-09-07T05:15:00.000Z Eightco Holdings (NASDAQ: ORBS) gibt einen Gesamtbestand von rund 380 Millionen US-Dollar bekannt, darunter Anteile an OpenAI und Beast Industries sowie mehr als 16.000 ETH und fast 302 Millionen WLD-Token https://www.biopharmawatch.com/news/ORBS/eightco-holdings-assets-openai-beast-industries BiopharmaWatch en 2026-09-07T05:04:00.000Z Eightco Holdings (NASDAQ : ORBS) annonce un actif total d'environ 380 millions de dollars, comprenant notamment OpenAI, Beast Industries, plus de 16 000 jetons ETH et près de 302 millions de jetons WLD https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-appoints-on365-investor-relations-adviser BiopharmaWatch en 2026-09-07T02:00:00.000Z Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser https://www.biopharmawatch.com/news/ROIV/roivant-phase-2-phocus-study-results-ers-congress-2026 BiopharmaWatch en 2026-09-06T05:00:00.000Z Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call